EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Recent advances in therapeutic strategies for Alzheimer's and Parkinson's disease using protein/peptide co‐modified polymer nanoparticles

Ramesha Hanumanthappa, Aravind Parthasarathy, Geetha B Heggannavar, Kiran Pc, Hemalatha Nanjaiah, Ramhari Kumbhar, Kuramkote Shivanna Devaraju iD

Neuroprotection · 2024-12 · 2 (4) · 255-275

DOI: 10.1002/nep3.60 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Neuroprotection, online erschienen am 28.11.2024. Verfasst von Ramesha Hanumanthappa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Neurochemistry Lab, Department of Biochemistry Karnatak University Dharwad Karnataka India. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The blood‐brain barrier (BBB), which protects the brain from foreign molecules, makes delivery of drugs to the central nervous system is challenging. Nanoparticles (NPs) have been used over the past decade as drug delivery systems for the treatment of many disorders with great results. However, the effectiveness of NPs in delivering drugs to the brain for the treatment of Alzheimer's disease (AD) and Parkinson's disease (PD) is limited by the BBB. A recent breakthrough in nanotechnology delivery systems involves the use of surface‐modified polymer NPs that enhance drug absorption and transport across the BBB; however, the technology still has some limitations. Studies conducted over the past few years have demonstrated that NPs modified with peptides or proteins can effectively cross the BBB via specific receptors, thus enhancing their delivery efficiency. In this review, we explore the use of polymer NPs combined with peptides and proteins for the treatment of AD and PD. This discussion focuses on the pathophysiology of these diseases, the BBB, and the potential of therapeutics based on co‐modifying NPs with peptides and proteins. Additionally, we outline future directions for the use of polymer NPs conjugated with these biomolecules.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer's diseaseParkinson's diseaseblood–brain barrierpeptidespolymersproteins

Autor:innen und Institutionen

  • Neurochemistry Lab, Department of Biochemistry Karnatak University Dharwad Karnataka India.
  • Department of Medicine, Cardiovascular Center Medical College of Wisconsin Milwaukee WI USA.
  • Department of Chemistry Karnatak University Dharwad Karnataka India.
  • Department of Microbiology and Immunology University of Maryland School of Medicine Baltimore MD USA.
  • Department of Neurology Johns Hopkins University School of Medicine Baltimore MD USA.

ORCID-Profile: Kuramkote Shivanna Devaraju

Zitieren

APA

Hanumanthappa, R., Parthasarathy, A., Heggannavar, G. B., Pc, K., Nanjaiah, H., Kumbhar, R., & Devaraju, K. S. (2024). Recent advances in therapeutic strategies for Alzheimer's and Parkinson's disease using protein/peptide co‐modified polymer nanoparticles. Neuroprotection, 2(4), 255-275. https://doi.org/10.1002/nep3.60

Vancouver

Hanumanthappa R, Parthasarathy A, Heggannavar GB, Pc K, Nanjaiah H, Kumbhar R, et al. Recent advances in therapeutic strategies for Alzheimer's and Parkinson's disease using protein/peptide co‐modified polymer nanoparticles. Neuroprotection. 2024;2(4):255-275. doi:10.1002/nep3.60

BibTeX
@article{Hanumanthappa2024,
  author = {Hanumanthappa, Ramesha and Parthasarathy, Aravind and Heggannavar, Geetha B and Pc, Kiran and Nanjaiah, Hemalatha and Kumbhar, Ramhari and Devaraju, Kuramkote Shivanna},
  title = {Recent advances in therapeutic strategies for Alzheimer's and Parkinson's disease using protein/peptide co‐modified polymer nanoparticles},
  journal = {Neuroprotection},
  year = {2024},
  volume = {2},
  number = {4},
  pages = {255--275},
  doi = {10.1002/nep3.60}
}
Kostenlos starten →